Robert Hershberg

Dr. Hershberg is a Venture Partner at Frazier Healthcare Partners, where he has been working with the firm’s portfolio companies as an advisor for over ten years. Dr. Hershberg was previously Executive Vice President and Head of Business Development & Global Alliances and served as a member of the Executive Committee, of Celgene Corp. until the company’s acquisition by Bristol-Myers Squibb in 2019. He joined Celgene in 2014 to lead the company’s efforts in Immuno-Oncology and was promoted to Executive Vice President and Chief Scientific Officer in 2016. Prior to Celgene, Dr. Hershberg was the President and Chief Executive Officer of VentiRx Pharmaceuticals, a biopharmaceutical company which he co-founded in 2006 and led through its transformational partnership with Celgene. He also previously served as Senior Vice President and Chief Medical Officer of Dendreon Corporation, where he led the clinical, regulatory, and biometrics groups for the development of Provenge® in metastatic prostate cancer. Early in his career, Dr. Hershberg served as an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Hershberg currently serves as a clinical faculty member at the University of Washington School of Medicine and is a member of the board of directors of Adaptive Biotechnologies, NanoString Technologies, Silverback Therapeutics, and Recursion Pharmaceuticals. He completed his undergraduate and medical degrees at the University of California, Los Angeles, and received his Ph.D. at the Salk Institute for Biological Studies.